PharmaCyte Biotech (NASDAQ: PMBC) is a clinical stage biotechnology company that develops treatments for cancer and diabetes using a proprietary cellulose based live cell encapsulation known as “Cell-in-a-Box®.” PharmaCyte cancer treatment encapsulates genetically modified live cells, which can convert an inactive chemotherapy drug (ifosfamide) into its “cancer-killing” form. The encapsulated live cells are placed as close to a cancerous tumor as possible, then the patient is intravenously given ifosfamide at one-third normal dose. When ifosfamide comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. PharmaCyte is also developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes using the Cell-in-a-Box® technology. For more information, visit the company’s website at www.pharmacyte.com